You are here

FDA Advisors Recommend Approval of Anoro Ellipta (Umeclidinium/Vilanterol) for Treatment of COPD

Final approval decision expected in December (September 10)

The FDA’s Pulmonary–Allergy Drugs Advisory Committee (PADAC) has voted 11 to 2 that the efficacy and safety data provide substantial evidence to support approval of umeclidinium/vilanterol (UMEC/VI, 62.5/25-mcg dose, GlaxoSmithKline/Theravance) for the long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Anoro Ellipta is the proposed proprietary name for UMEC/VI, a combination of two investigational bronchodilator molecules — GSK573719 or umeclidinium bromide (UMEC), a long-acting muscarinic antagonist (LAMA), and vilanterol (VI), a long-acting beta2 agonist (LABA), administered using the Ellipta inhaler.

The FDA Advisory Committee also voted that the safety of the investigational drug has been adequately demonstrated at the 62.5/25-mcg dose for the proposed indication (10 yes, 3 no), and that the efficacy data provided substantial evidence of a clinically meaningful benefit for UMEC/VI 62.5/25 mcg once daily for the long-term maintenance treatment of airflow obstruction in COPD (13 yes, 0 no).

The Prescription Drug User Fee Act (PDUFA) goal date for UMEC/VI is December 18, 2013.

Source: GSK; September 10, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs